Scholarlink

Background <p>Studies have demonstrated the importance of the androgen receptor (AR) in the development of bladder cancer and have proposed it as a potential biomarker or therapeutic hypothesis. However, the relationship between AR expression and both clinical features of patients and intrinsic tumor characteristics remains uncertain.</p> Aims <p>To evaluate the association between AR immunohistochemical expression and clinical as well as pathological characteristics of bladder cancer.</p> Methods <p>We conducted a retrospective cohort including patients diagnosed with bladder cancer through transurethral resection of the bladder (TURB) between 2016 and 2021. For each case, AR immunoexpression was tested and analyzed in relation to sex, age, smoking history, number of tumor foci, tumor size, vascular invasion, histological grade, carcinoma in situ, and pathological stage.</p> Results <p>Low AR expression was observed in 97.5% of cases, while high expression was identified in 1.4% and indeterminate cases accounted for 1.1% of the cohort. AR immunoexpression was not related to clinical or pathological variables.</p> Conclusion <p>No significant associations were identified between AR expression and clinical or pathological variables, suggesting that its potential role as a biomarker in bladder cancer warrants further investigation.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigation of androgen receptor expression in urothelial carcinoma of the bladder

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • André Luís Nunes Avelino,
  • Felipe Dias Gonçalves,
  • Jhonas Nathanael Menezes Ferreira,
  • Gislane Rocha Vasconcelos,
  • Conceição Aparecida Dornelas

摘要

Background

Studies have demonstrated the importance of the androgen receptor (AR) in the development of bladder cancer and have proposed it as a potential biomarker or therapeutic hypothesis. However, the relationship between AR expression and both clinical features of patients and intrinsic tumor characteristics remains uncertain.

Aims

To evaluate the association between AR immunohistochemical expression and clinical as well as pathological characteristics of bladder cancer.

Methods

We conducted a retrospective cohort including patients diagnosed with bladder cancer through transurethral resection of the bladder (TURB) between 2016 and 2021. For each case, AR immunoexpression was tested and analyzed in relation to sex, age, smoking history, number of tumor foci, tumor size, vascular invasion, histological grade, carcinoma in situ, and pathological stage.

Results

Low AR expression was observed in 97.5% of cases, while high expression was identified in 1.4% and indeterminate cases accounted for 1.1% of the cohort. AR immunoexpression was not related to clinical or pathological variables.

Conclusion

No significant associations were identified between AR expression and clinical or pathological variables, suggesting that its potential role as a biomarker in bladder cancer warrants further investigation.

Clinical trial number

Not applicable.